Status:

UNKNOWN

Human Amniotic Epithelial Cells Prevent Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transplantation

Lead Sponsor:

Peking University People's Hospital

Collaborating Sponsors:

Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China

Conditions:

Acute-graft-versus-host Disease

Eligibility:

All Genders

8-70 years

Phase:

NA

Brief Summary

This is a Single arm clinical study evaluating the safety and efficacy of hAECs in preventing aGVHD after HSCT.

Detailed Description

A dose escalation study evaluating the safety and efficacy of human amniotic epithelial cells( hAECs) in preventing acute graft-versus-host(aGVHD) disease after hematopoietic stem cell transplantation...

Eligibility Criteria

Inclusion

  • Standard risk GVHD patients with hematological malignancies;
  • High risk GVHD patients with hematological malignancies: haplotype hematopoietic stem cell transplantation patients, donor is female or more than 30 years old;
  • Well informed about this study and signed a consent form before the trial;
  • Left ventricular ejection fraction (LVEF) ≧ 50%, no evidence of pericardial effusion;
  • No evidence of lung infection by X-rays examination;
  • Eastern cooperative oncology group (ECOG) performance status of 0 or 1, Hematopoietic cell transplantation - specific comorbidity index (HCT-CI) of 0, 1, 2;
  • Normal liver and kidney function;

Exclusion

  • Reduce pretreatment dose or secondary transplantation;
  • participate other clinical trials within 2 months before this study;
  • Female, 1) pregnant/nursing period, or 2) have a pregnancy plan during the study period, or 3) have fertility and cannot take effective contraception;
  • History of severe allergic disease or is allergic to one or more drugs;
  • Patients who are considered unsuitable for the study by the investigator.

Key Trial Info

Start Date :

July 1 2020

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

July 1 2022

Estimated Enrollment :

27 Patients enrolled

Trial Details

Trial ID

NCT03764228

Start Date

July 1 2020

End Date

July 1 2022

Last Update

October 1 2020

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Peking University Institute of Hematology

Beijing, Beijing Municipality, China, 100044

2

Peking University People's Hospital

Beijing, Beijing Municipality, China, 100044